NEW YORK (TheStreet) -- Valeant Pharmaceuticals International n">said it remains on the outlook for other companies, including makers of innovative contact lenses, as it attempts to take over Allergan , Reuters reports. On a conference call with investors, Valeant CEO Michael Pearson said the company won't be content to remain the number four global player in the contact lens industry. Shares of Valeant Pharmaceuticals are down -7.02% to $117 on very heavy trading volume this afternoon. Must Read: Warren Buffett's 25 Favorite Stocks STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months.